Loading clinical trials...
Loading clinical trials...
A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA
This study will compare the effectiveness and safety of two different doses of temsirolimus (Torisel).
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Mercy Research Institute
Miami, Florida, United States
Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111)
East Orange, New Jersey, United States
Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley
Oklahoma City, Oklahoma, United States
Mercy Hospital Oklahoma City-Oncology Infusion
Oklahoma City, Oklahoma, United States
Amy Shen, RPh
Seattle, Washington, United States
VA Puget Sound Health Care System
Seattle, Washington, United States
St George Hospital
Kogarah, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Royal Hobart Hospital
Hobart, Tasmania, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Start Date
March 1, 2011
Primary Completion Date
November 1, 2015
Completion Date
June 1, 2018
Last Updated
May 20, 2019
101
ACTUAL participants
temsirolimus
DRUG
temsirolimus
DRUG
Lead Sponsor
Pfizer
NCT06667687
NCT05623982
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT03314974